van Walraven C, Stiell I G, Wells G A, Hébert P C, Vandemheen K
Clinical Epidemiology Unit, University of Ottawa, Ottawa, Ontario, Canada.
Ann Emerg Med. 1998 Nov;32(5):544-53. doi: 10.1016/s0196-0644(98)70031-9.
The benefit of Advanced Cardiac Life Support (ACLS) medications during cardiac resuscitation is uncertain. The objective of this study was to determine whether the use of these medications increased resuscitation from in-hospital cardiac arrest.
A prospective cohort of patients undergoing cardiac arrest in 1 of 5 academic hospitals was studied. Patient and arrest factors related to resuscitation outcome were recorded. We determined the association of the administration of ACLS drugs (epinephrine, atropine, bicarbonate, calcium, lidocaine, and bretylium) with survival at 1 hour after resuscitation.
Seven hundred seventy-three patients underwent cardiac resuscitation, with 269 (34. 8%) surviving for 1 hour. Use of epinephrine, atropine, bicarbonate, calcium, and lidocaine was associated with a decreased chance of successful resuscitation (P <.001 for all except lidocaine, P <.01). While controlling for significant patient factors (age, gender, and previous cardiac or respiratory disease) and arrest factors (initial cardiac rhythm, and cause of arrest), multivariate logistic regression demonstrated a significant association between unsuccessful resuscitation and the use of epinephrine (odds ratio . 08 [95% confidence interval .04-.14]), atropine (.24 [.17-.35]), bicarbonate (.31 [.21-.44]), calcium (.32 [.18-.55]), and lidocaine (.48 [.33-.71]). Drug effects did not improve when patients were grouped by their initial cardiac rhythm. Cox proportional hazards models that controlled for significant confounders demonstrated that survivors were significantly less likely to receive epinephrine (P <. 001) or atropine (P <.001) throughout the arrest.
We found no association between standard ACLS medications and improved resuscitation from in-hospital cardiac arrest. Randomized clinical trials are needed to determine whether other therapies can improve resuscitation from cardiac arrest when compared with the presently used ACLS drugs.
高级心脏生命支持(ACLS)药物在心脏复苏过程中的益处尚不明确。本研究的目的是确定使用这些药物是否能提高院内心脏骤停患者的复苏成功率。
对五家学术医院之一的心脏骤停患者进行前瞻性队列研究。记录与复苏结果相关的患者和骤停因素。我们确定了ACLS药物(肾上腺素、阿托品、碳酸氢盐、钙剂、利多卡因和溴苄铵)的使用与复苏后1小时存活情况之间的关联。
773例患者接受了心脏复苏,其中269例(34.8%)存活1小时。使用肾上腺素、阿托品、碳酸氢盐、钙剂和利多卡因与复苏成功几率降低相关(除利多卡因外,其他均P<.001,利多卡因P<.01)。在控制了重要的患者因素(年龄、性别和既往心脏或呼吸系统疾病)和骤停因素(初始心律和骤停原因)后,多因素逻辑回归显示复苏失败与使用肾上腺素(比值比0.08[95%置信区间0.04 - 0.14])、阿托品(0.24[0.17 - 0.35])、碳酸氢盐(0.31[0.21 - 0.44])、钙剂(0.32[0.18 - 0.55])和利多卡因(0.48[0.33 - 0.71])之间存在显著关联。根据初始心律对患者进行分组时,药物效果并未改善。控制了重要混杂因素的Cox比例风险模型显示,在整个骤停过程中,存活者接受肾上腺素(P<.001)或阿托品(P<.001)的可能性显著降低。
我们发现标准ACLS药物与提高院内心脏骤停患者的复苏成功率之间无关联。需要进行随机临床试验来确定与目前使用的ACLS药物相比,其他疗法是否能改善心脏骤停患者的复苏情况。